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Background: Spasticity of muscles is a common consequence of central nervous system impairment. Traditionally,
neurological rehabilitation for spasticity has involved occupational and physical therapy; however, increasingly
Botulinum toxin–A injections may be provided. Injection effects are temporary. Consequently, understanding the
effect of adjunct physical therapies will help inform multimodal rehabilitation decisions. Presently, these effects are
not known. This systematic review will identify and summarize evidence on physical therapies used after Botulinum
toxin-A injection to improve motor function in adults with neurological impairments.
Method: Systematic searching of seven electronic databases will occur to identify relevant randomized trials.
Available trial data will be extracted into a list of pre-defined primary outcomes, including range of movement,
spasticity and functional limb use. Pre-defined secondary outcomes will also be reviewed where trials have these
data available for reporting. Effects will be expressed as mean differences or standardized mean differences with
95% confidence intervals (CI). Where possible, comparable results will be meta-analyzed, and a summary of the
available pool of evidence produced.
All randomized controlled trials will be rated using the PEDro methodological quality scale. Where possible, study
data will be meta-analyzed using RevMan 5 Software. The protocol was registered in PROSPERO international
prosepective register of systematic reviews (PROSPERO 2011:CRD42011001491).
Discussion: Review results will be the most comprehensive answer available to the following question: Are physical
therapies clinically effective after Botulinum toxin-A injections in adults with neurological spasticity? Results will
inform healthcare providers and managers who determine who gets access to and provision of Botulinum toxin-A
injection and whether this is done with or without physical therapies. Results will inform the clinicians who conduct
physical therapy following injection. This protocol provides readers with the scope and depth of a search that will
ultimately answer a complex and pressing treatment question. The variability of current practice and high level of
expense associated with multimodal rehabilitation means review results will be more useful and less contestable if
the protocol is revealed in full through advance publication.
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Spasticity is one negative symptom which can occur fol-
lowing central nervous system impairment [1,2]. Spasti-
city is defined as a velocity-dependent increase in stretch
reflex with exaggerated tendon jerks [1]. This motor dis-
order can have a profound impact on health outcomesCorrespondence: biancakinnear@hotmail.com
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reproduction in any medium, provided the orand quality of life. It is associated with pain [3], and
often has a negative impact on function, self-esteem and
body image [4]. General health can suffer as spasticity
leads to difficulties in hygiene and maintaining skin in-
tegrity in affected limbs with consequent infection com-
mon [5]. Treatment of spasticity and management of
consequences of this motor disorder is an unending, ex-
pensive and time intensive task for health services and
the people affected by it, with results recognized to be
‘less than satisfactory’ [6]. There is an urgent need toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In the past decade, traditional rehabilitation for this
motor disorder, such as occupational and physical ther-
apy, has been augmented by pharmacotherapy, such as
Botulinum Toxin-A, which has been demonstrated to
reduce spasticity [8]. The effect from pharmacotherapy
is temporary so there is interest in the adjunct effects of
physical therapies, since the rehabilitation goals of
patients are long term. Typical goals include: increasing
range of motion (ROM), improving limb position and
performance of activities, and ensuring skin integrity [9-
11].
Following BoNT-A injection, physical therapies can be
used, such as stretching, casting, strengthening exercises,
splinting and movement training often in the context of
functional activities where normal movement patterns
are encouraged [2,6,12,13]. These physical therapies
post-BoNT-A injection are thought to improve ROM
and function in patients with motor disorders following
neurological impairment. Both BoNT-A and physical
therapies have been shown, together and separately, to
have an impact on health outcomes, such as walking
ability [14,15]. To date, however, no study has examined
the cumulative evidence regarding combined BoNT-A
and physical therapies for treatment of spasticity in
upper or lower limbs of adult patients with neurological
impairment. Given the cost and scale of the service pro-
vided, and the breadth and complexity of health and
quality of life problems involved, a review that provides
a comprehensive summary of evidence relating to this
problem and intervention is urgently needed.
Methods
This systematic review will identify and summarize evi-
dence on physical therapies used after Botulinum toxin-
A injection to improve motor function in adults with
neurological impairments. In summarizing evidence, the
review will evaluate the effectiveness of physical therap-
ies used post-BoNT-A injection for improving motor
function in this patient population. Inclusion criteria for
studies in the review now follow.
Types of studies
Eligible studies will be randomizsed controlled trials and
quasi-randomized controlled trials. Only the first arm of
cross-over trials will be included.
Types of participants
Eligible participants will be aged 16 years and over with
a neurological impairment (central nervous system dam-
age) and have received BoNT-A injections in their limb
muscles up to three months prior to study rehabilitation
commencement for spasticity management.Types of interventions
Physical rehabilitation interventions provided to patients
who have received BoNT-A to the upper or lower limb,
including casting, splinting, stretching, movement train-
ing, exercises, strengthening or electrical stimulation, are
compared with sham or no physical therapy.
Types of outcome measures
Primary outcomes
1. Measures of range of movement, such as
goniometry or torque-controlled range of
movement.
2. Measures of improved functional limb use or active
movement of the affected limb as measured on the
Action Research Arm Test, the Motor Activity Log
(assessment or self report), Wolf Motor Function
Test, Fugl-Meyer assessment of motor function, Box
and Blocks test, velocity of gait (meters/second) and
step length.
3. Measures of reduced spasticity as measured by the
Modified Ashworth Scale.
Secondary outcomes
1. Health-related quality of life
2. Caregiver/attendant care time and/or number
3. Discharge destination/living situation
4. Rehabilitation length of stay
5. Mortality
6. Adverse events
Studies will be excluded if:
i) The study design investigated diagnostic or
prognostic factors/relationships
ii) Less than 50% of the interventions were applied to
the upper or lower limb
iii) Outcomes from physical therapies were not able to
be differentiated from the outcomes of other
therapies provided simultaneously to participants.
Search strategy
The following databases will be electronically searched for
all available years: PEDro, CENTRAL, Pub Med, EMBASE,
CINAHL, National Research Register, Meta Registry of
Controlled Trials and Occupational Therapy Systematic
Evaluation of Effectiveness database (OTseeker). The search
will not be limited by date or publication status. We will
check the reference lists of any eligible studies identified for
further relevant studies. Unpublished, non-peer reviewed
sources, such as conference abstracts, will not be included
(refer to appendix 1.)
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studies for inclusion against the eligibility criteria. They
will examine the title and abstract and, where necessary,
the full text of studies to assess if they are eligible for in-
clusion. If they cannot reach agreement by discussion, a
third author will make the final decision about eligibility.
Data extraction
Two authors will independently use a standard form to
extract study characteristics and outcome data from the
studies. Discrepancies will be checked against the ori-
ginal data. A third author will make the final decision if
there is a disagreement. One author (BK) will enter data
in Revman meta-analysis software (Review Manager
(RevMan) [Computer program]. Version 5.1. Copen-
hagen: The Nordic Cochrane Centre, The Cochrane Col-
laboration, 2011) [16]. Data will be reported during
therapy as well as at end of therapy. Any outcomes mea-
sured after therapy has finished will be grouped as less
than one month, one to six months, and over six
months.
Quality assessment
Methodological quality will be assessed using the PEDro
scale by one reviewer (BK). The PEDro scale has estab-
lished reliability and provides a score out of 10 [17].
Studies which attain a PEDro score of 7 or greater are
considered ‘high quality’, those with a PEDro score of 5
or 6 are considered ‘moderate quality’ and those with a
PEDro score of 4 or less are considered ‘poor quality’ in
terms of study methods and susceptibility to bias [18].
Adequacy of concealment will additionally be rated
using the procedure outlined by Schulz [19]. The meth-
odological quality of included observational studies will
be assessed independently by two raters using the
MOOSE (Meta-analysis Of Observational Studies in Epi-
demiology) guidelines [20]. Scores will be based on all
information available from both the published version
and the authors themselves. No trial will be excluded on
the basis of poor quality.
Data analysis
Analysis of covariance-adjusted between-group means
and standard deviations will be extracted in preference
to between-group differences in change scores, and
between-group differences in change scores will be
extracted in preference to between group differences in
final scores. If studies reported data as medians and
interquartile ranges, medians will be used as a surrogate
for means and standard deviations were estimated as
80% of the interquartile range (studies which do not re-
port an interquartile range (IQR) will be excluded from
the meta-analysis). For continuous outcome measures, a
pooled estimate of treatment effect will be determinedby calculating the mean difference and the correspond-
ing 95% CIs. For dichotomous outcome measures, a
pooled estimate of treatment effect will be calculated for
each outcome across studies using risk ratio where ap-
propriate and the corresponding 95% confidence inter-
vals (CIs). Time-to-event data will be analyzed using the
hazard ratio and 95% CIs as required. When conducting
a meta-analysis combining results from crossover stud-
ies, the first-arm data only will be used. In the event of
missing, incomplete or unclear data, the original investi-
gators will be contacted. If it is not possible to obtain
the necessary data for analysis, the study results will be
described in the text and will not be included in the
meta-analysis.
When there are at least two clinically homogenous
studies (studies which investigated the effect of similar
interventions on similar populations and reported simi-
lar outcomes) meta-analysis will be considered. In such
circumstances, the I2 statistic will be used to quantify
the heterogeneity of outcomes and informed decisions
about whether to pool data. Where I2 is greater than
30% in the presence of significant chi-squared test result
(P-value< 0.10), this will be interpreted as indicating
heterogeneity [21]. If there is significant heterogeneity
(over 50%), data will not be pooled.
We will enter data extracted from included studies
into RevMan software [16]. Meta-analyses of clinically
homogenous therapies will be conducted using a fixed-
effects model. Where heterogeneity is substantial
(I2> 50%), the possible causes of heterogeneity will be
explored in sensitivity analyses in which individual stud-
ies will be omitted one at a time. Should heterogeneity
not be able to be explained, a random-effects model will
be used.
Sensitivity analysis
The robustness of our results will be tested through sen-
sitivity analyses excluding unpublished studies, small
studies and studies with a PEDro score less than 5.
Discussion
Spasticity can be a significant causal factor in patients’
decreasing functional limb use and mobility, often com-
pounding the difficulties faced in rehabilitation by
patients with motor weakness and impairment. Review-
ing the effectiveness of therapies provided after BoNT-A
and the effects on spasticity, movement and function
will provide much needed guidance to therapists, as well
as policy and funding guidance to health departments in
how to provide the most effective interventions.
There are currently no evidence-based guidelines for
the physical rehabilitation that should be provided to
adults with neurological impairment who have received
Botulinum toxin–A injections in the upper or lower
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lines [22] and national treatment guidelines [23] do not
recommend a protocol for physical rehabilitation when
provided as an adjunct to Botulinum toxin injection. In-
stead, evidence is available from completed and ongoing
trials in the area of stroke rehabilitation where different
post Botulinum toxin injection physical rehabilitation
interventions are compared with each other, other forms
of therapy or no therapy. Internationally, Botulinum
toxin-A has regulatory approval for upper and lower
limb injection in adults with neurological conditions.
This review considers whether physical rehabilitation
following such injection has an effect on functional
outcomes.
Appendix 1
A.1. PEDro Search Strategy
1. Spasticity
2. Botulinum toxin
A.2. CENTRAL Search Strategy
1. Spasticity (key word, title, abstract)
2. Botulinum toxin (key word, title, abstract)
3. Therapy (key word, title, abstract)
4. Adults (key word, title, abstract)
A.3. PubMed Search Strategy
1. Muscle spasticity/
2. Spastic.tw
3. Muscle tonus
4. Hyperton$
5. ((muscle* or muscular) adj3 (spasm* or cramp or
spastic* or clonus).ab, ti.
6. or/1–5
7. Stroke/
8. Cerebrovascular disorders
9. exp brain ischemia
10. brain/or exp intracranial arterial diseases
11. exp “intracranial embolism and thrombosis”
12. exp intracranial haemorrhages/
13. ((stroke$ or post stroke$ or post- stroke$ or cva$).
tw.)
14. ((cerebrovascular cerebral vascular) adj3 (accident?
or insult?).tw.)
15. (((cerebral or brain$ or vertebrobasilar) adj5 (infarc
$ or isch?emi$ or thrombo$ or apoplexy or emboli
$)).t.w.)
16. ((cerebral or brain or subarachnoid) adj5
(haemorrhage or hemorrhage or haematoma or
hematoma or bleed)).tw.)
17. (((trauma$ or acquired) adj5 brain injur$).tw.)18. (exp brain injuries/)
19. brain damage, chronic/or brain injury, chronic/)
20. (exp craniocerebral trauma/or head injuries, closed/
or intracranial hemorrhage, traumatic/)
21. (exp encephalitis/or exp meningitis, viral/or brain
abscess/or exp central nervous system infections)
22. ((encephalitis or meningitis or brain abscess or
brain infection$ or cerebral infection$).tw.)
23. (exp Brain Neoplasms/)
24. (((brain or cerebr$) adj5 (neoplasm$ or lesion$ or
tumor$)).tw.)
25. Brain injuries/
26. Traumatic brain injury*
27. Spinal injuries/
28. exp Spinal cord injuries
29. (spinal cord adj3 (injur* or damage* or contusion*
or lacerat* or trauma*)).ab,ti.
30. 28 or 29 or 30
31. Cerebral palsy or CP
32. cerebral pals$.tw
33. Multiple sclerosis or MS
34. ((((“Multiple Sclerosis”[mh]) OR (“Myelitis,
Transverse”[mh:noexp]) OR (“Demyelinating
Diseases”[mh:noexp]) OR (“Encephalomyelitis, Acute
Disseminated”[mh:noexp]) OR (“Optic
Neuritis”[mh])) OR (((“multiple sclerosis”) OR
(“neuromyelitis optica”) OR (“transverse myelitis”)
OR (encephalomyelitis) OR (devic) OR (“optic
neuritis”)) OR (“demyelinating disease*”) OR (“acute
disseminated encephalomyelitis”)))
35. Hemiplegia/
36. Hemiplegi$.tw
37. Monoplegi$.tw
38. Triplegi$.tw
39. Quadriplegia/
40. Quadriplegi$.tw
41. or/7–40
42. exp Botulinum Toxins/
43. Botulinum toxin type a/
44. Botulin$.tw
45. Botox.tx
46. Dysport. tw
47. Muscle spasticity/dt [Drug therapy]
48. Muscle tonus/de [Drug effects]
49. or/42–48
50. physical therapy.tw
51. Physical therapy modalities/
52. Exercise therapy/
53. Occupational therapy/
54. Exercise movement techniques/
55. Rehabilitation/
56. Splints/
57. Casts, Surgical/
58. Treatment outcome/
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60. or/46–55
61. clinical trial.pt
62. controlled clinical trial.pt.
63. clinical trials as topic.sh.
64. trial.ti.
65. randomi?ed.ab.
66. randomized controlled trial.pt
67. randomly.a.b.
68. or/57–63
69. humans.sh
70. 6 and 41 and 49 and 60 and 68 and 69
A.4. CINAHL Search Strategy
1. Muscle spasticity
2. Muscle tonus
3. Muscle hypertonia
4. Muscle cramp
5. Muscles
6. Or/1–5
7. Stroke
8. Cerebrovascular disorders
9. Cerebral ischemia
10. Brain
11. Intracranial arterial diseases
12. Intracranial embolism and thrombosis
13. Cerebral aneurysm
14. Hemorrhage
15. Subarachnoid hemorrhage
16. Infarction
17. Hypoxia, brain
18. Brain death
19. Brain damage, chronic
20. Hypoxia-Ischemia, Brain
21. Encephalitis
22. Meningitis, viral
23. Brain abscess
24. Brain neoplasms
25. Brain injuries
26. Spinal injuries
27. Spinal cord injuries
28. Spinal cord neoplasms
29. Cerebral palsy
30. Multiple sclerosis
31. Myelitis
32. Encephalomyelitis, acute disseminated
33. Demyelinating autoimmune diseases, CNS
34. Hemiplegia
35. Quadriplegia
36. Or/7–35
37. Botulinum Toxins
38. Botulism
39. Drug Therapy40. or/37–39
41. Physical therapy
42. Physical therapy assessment
43. Physical therapy service
44. Therapeutic exercise
45. Occupational Therapy
46. Occupational Therapy assessment
47. Rehabilitation
48. Splints
49. Casts
50. Treatment outcomes
51. Orthoses
52. Or/41–51
53. Human
54. Adult
55. 53 or 54
56. 6 and 36 and 40 and 52 and 55
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